Paloma Partners Management Co boosted its stake in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 6.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,684 shares of the medical research company’s stock after buying an additional 842 shares during the period. Paloma Partners Management Co’s holdings in PRA Health Sciences were worth $958,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. First Bank & Trust raised its position in PRA Health Sciences by 1.7% in the first quarter. First Bank & Trust now owns 3,159 shares of the medical research company’s stock worth $206,000 after buying an additional 54 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in PRA Health Sciences by 0.6% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 21,752 shares of the medical research company’s stock worth $1,199,000 after buying an additional 130 shares during the last quarter. Forward Management LLC increased its position in shares of PRA Health Sciences by 5.0% in the first quarter. Forward Management LLC now owns 4,762 shares of the medical research company’s stock valued at $310,000 after buying an additional 226 shares in the last quarter. 1st Global Advisors Inc. increased its position in shares of PRA Health Sciences by 2.2% in the first quarter. 1st Global Advisors Inc. now owns 11,265 shares of the medical research company’s stock valued at $735,000 after buying an additional 238 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of PRA Health Sciences by 7.1% in the first quarter. Legal & General Group Plc now owns 9,943 shares of the medical research company’s stock valued at $649,000 after buying an additional 663 shares in the last quarter.

PRA Health Sciences, Inc. (NASDAQ PRAH) remained flat at $74.08 during midday trading on Friday. The company’s stock had a trading volume of 613,493 shares. The stock has a market cap of $4.63 billion, a price-to-earnings ratio of 44.25 and a beta of 0.45. PRA Health Sciences, Inc. has a 12-month low of $46.52 and a 12-month high of $79.98. The stock’s 50 day moving average price is $75.01 and its 200 day moving average price is $66.37.

TRADEMARK VIOLATION NOTICE: “Paloma Partners Management Co Has $958,000 Position in PRA Health Sciences, Inc. (NASDAQ:PRAH)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/04/paloma-partners-management-co-boosts-stake-in-pra-health-sciences-inc-nasdaqprah-updated-updated-updated.html.

Several equities research analysts have recently commented on the stock. Citigroup Inc. reiterated a “buy” rating and set a $90.00 price target (up previously from $73.00) on shares of PRA Health Sciences in a research report on Wednesday, June 28th. Jefferies Group LLC lifted their price objective on shares of PRA Health Sciences from $72.00 to $72.50 and gave the stock a “buy” rating in a research note on Friday, April 28th. Credit Suisse Group reissued an “outperform” rating and set a $76.00 price objective (up previously from $69.00) on shares of PRA Health Sciences in a research note on Tuesday, June 6th. Bank of America Corporation started coverage on shares of PRA Health Sciences in a research note on Monday, June 26th. They issued a “buy” rating and a $89.00 price target on the stock. Finally, BidaskClub lowered shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. PRA Health Sciences has a consensus rating of “Buy” and a consensus target price of $73.00.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.